A pharmacy has completed quarantining its on-shelf stock from a Class I recall of a blood-pressure medicine, lot BP-7782, but its records show several patients already received the affected lot. What is the pharmacy's most appropriate next step in responding to this recall?
- ATake no further action because patients already in possession of the medicine are beyond the recall's reach
- BSubstitute a different manufacturer's product for those patients without contacting them about the recall at all
- CNotify the affected patients in line with the recall instructions so they can stop using or return the product Correct
- DReport each affected patient individually to the FDA before taking any other action about the recall
Why A is wrong: Treating dispensed product as out of scope is tempting once shelves are cleared, but a Class I recall poses serious risk to the very patients holding the affected lot.
Why B is wrong: Switching suppliers may help future fills, but silently substituting does not warn patients already holding a dangerous lot and skips the required notification.
Why C is correct: A Class I recall involves serious risk, so contacting patients who received the affected lot per the notice is the recognised next step after removing on-shelf stock.
Why D is wrong: The pharmacy acts on the firm's recall communication and notifies patients; routing individual patient names to the FDA first is not the prescribed pharmacy response.